Loading...
Loading...
Repligen Corp RGEN reported Q1 FY23 sales of $182.66 million, down 12% Y/Y as reported, beating the consensus of $181.43 million.
- Adjusted EPS fell 30.4% to $0.64, beating the consensus of $0.59.
- The company expanded its single-use fluid management offering by acquiring FlexBiosys Inc recently. "Strategically, we continue to build out our Fluid Management portfolio with the April acquisition of FlexBiosys, adding single-use bags to our suite of products," Chief Executive Officer J. Hunt said.
- Adjusted gross profit in Q1 was $100.8 million, down 19% Y/Y. The adjusted gross margin contracted 520 basis points to 55.2%, compared to 60.4% a year ago.
- Adjusted EBITDA in Q1 was $48.9 million, lower than $72.2 million a year ago.
- The cash and equivalents were $618 million.
- The company expects 2023 to be a challenging year due to a slower recovery in order growth in Asia Pacific, particularly in China.
- FY23 Guidance: Repligen lowered its guidance for FY23.
- Total reported revenue is expected to be in the range of $720-$760 million, a 5% downward adjustment to the previous guidance of $760-$800 million. The consensus estimate stands at $779.98 million.
- The gross margin is expected to be 52%-53%, compared with previous guidance of 52.5%-53.5%.
- The company forecasts adjusted EPS of $2.35-$2.42, lower than the previous guidance of $2.61-$2.69. The consensus stands at $2.64.
Price Action: RGEN shares are up 5.5% at $161.98 during the market session on the last check Tuesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in